story of the week
Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial
Clin. Cancer Res 2022 May 16;[EPub Ahead of Print], CH Lee, R Motzer, H Emamekhoo, M Matrana, I Percent, JJ Hsieh, A Hussain, U Vaishampayan, S Liu, S McCune, V Patel, M Shaheen, J Bendell, AC Fan, BA Gartrell, OB Goodman, PG Nikolinakos, AR Kalebasty, Y Zakharia, Z Zhang, H Parmar, L Akella, K Orford, NM TannirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.